ARQULE INC(NSDQ:ARQL)
|
ArQule collaborates with pharmaceutical and biotechnology companies tosynthesize and optimize small molecules that have the potential to enterclinical development and become medicines. ArQule''s Parallel Track DrugDiscovery program integrates key technologies for high-throughput, automated synthesis of small molecules with technologies that enable more informed, intelligent decisions about what molecules to synthesize. ArQule also offers access to their high-throughput, automated synthesis and lead optimization platforms through technology licensing agreements.
|
# Employees: 113
|
|
Address: 19 Presidential Way,Woburn,MA,USA
|
|
Phone: 781 994-0300
|
Fax: 781 376-6019
|
|
Website: www.arqule.com
|
Email: wboni@ArQule.com
|
Sector: Medical
|
Industry: MED-DRUGS
|
Executive Officers
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
|
Last Earnings Date: 6/30/2008
|
|
Next Earnings Date(Expected): 11/6/2008
|
|
Mean EPS (Next Qtr): ($0.43)
|
|
Mean EPS (Year): ($1.58)
|
|
Mean Estimate(Long Term): ($0.01)
|
|
P/E Ratio(Based on EPS estimate): -0.010
|
|
Number of Estimates: 8
|
|
Shares Performance
|
Period
|
ARQL
|
Compare to S&P
|
| YTD |
-42.59 %
|
-30.53 %
|
| 4 Weeks |
-9.51 %
|
-8.99 %
|
| 12 Weeks |
-9.02 %
|
-3.26 %
|
Shares Information
|
Analyst Coverage: Y
|
Avg Volume: 154923
|
|
Shares Outstanding: 44M
|
Market Cap: $0.15B
|
| 52 Week High: $8.27
|
52 Week Low: $3.10
|
| P/E Ratio: -0.010
|
PEG Ratio: -0.010
|
|
Split: On 1/1/1990 ARQL split by factor of 2.000
|
Earnings Performance
EPS Growth in Last Quarter: -15.63 %
EPS Growth in Last Year: -2.78 %
Sales Growth in Last Quarter: -26.76 %
Sales Growth in Last Quarter: 15.57 %
Financials
|
Qtr Book Value: $2.50
|
|
Cash Flow/Share: ($0.01)
|
|
Change in Payout Ratio: -0.010
|
|
Price/Sales: 12.870
|
|
